BACKGROUND: Alzheimer disease results in progressive functional decline, leading to loss of independence. OBJECTIVE: To determine whether collaborative care plus 2 years of home-based occupational therapy delays functional decline. DESIGN: Randomized, controlled clinical trial. (ClinicalTrials.gov: NCT01314950). SETTING: Urban public health system. PATIENTS: 180 community-dwelling participants with Alzheimer disease and their informal caregivers. INTERVENTION: All participants received collaborative care for dementia. Patients in the intervention group also received in-home occupational therapy delivered in 24 sessions over 2 years. MEASUREMENTS: The primary outcome measure was the Alzheimer's Disease Cooperative Study Group Activities of Daily Living Scale (ADCS ADL); performance-based measures included the Short Physical Performance Battery (SPPB) and Short Portable Sarcopenia Measure (SPSM). RESULTS: At baseline, clinical characteristics did not differ significantly between groups; the mean Mini-Mental State Examination score for both groups was 19 (SD, 7). The intervention group received a median of 18 home visits from the study occupational therapists. In both groups, ADCS ADL scores declined over 24 months. At the primary end point of 24 months, ADCS ADL scores did not differ between groups (mean difference, 2.34 [95% CI, -5.27 to 9.96]). We also could not definitively demonstrate between-group differences in mean SPPB or SPSM values. LIMITATION: The results of this trial are indeterminate and do not rule out potential clinically important effects of the intervention. CONCLUSION: The authors could not definitively demonstrate whether the addition of 2 years of in-home occupational therapy to a collaborative care management model slowed the rate of functional decline among persons with Alzheimer disease. This trial underscores the burden undertaken by caregivers as they provide care for family members with Alzheimer disease and the difficulty in slowing functional decline. PRIMARY FUNDING SOURCE: National Institute on Aging.
BACKGROUND: Alzheimer disease results in progressive functional decline, leading to loss of independence. OBJECTIVE: To determine whether collaborative care plus 2 years of home-based occupational therapy delays functional decline. DESIGN: Randomized, controlled clinical trial. (ClinicalTrials.gov: NCT01314950). SETTING: Urban public health system. PATIENTS: 180 community-dwelling participants with Alzheimer disease and their informal caregivers. INTERVENTION: All participants received collaborative care for dementia. Patients in the intervention group also received in-home occupational therapy delivered in 24 sessions over 2 years. MEASUREMENTS: The primary outcome measure was the Alzheimer's Disease Cooperative Study Group Activities of Daily Living Scale (ADCS ADL); performance-based measures included the Short Physical Performance Battery (SPPB) and Short Portable Sarcopenia Measure (SPSM). RESULTS: At baseline, clinical characteristics did not differ significantly between groups; the mean Mini-Mental State Examination score for both groups was 19 (SD, 7). The intervention group received a median of 18 home visits from the study occupational therapists. In both groups, ADCS ADL scores declined over 24 months. At the primary end point of 24 months, ADCS ADL scores did not differ between groups (mean difference, 2.34 [95% CI, -5.27 to 9.96]). We also could not definitively demonstrate between-group differences in mean SPPB or SPSM values. LIMITATION: The results of this trial are indeterminate and do not rule out potential clinically important effects of the intervention. CONCLUSION: The authors could not definitively demonstrate whether the addition of 2 years of in-home occupational therapy to a collaborative care management model slowed the rate of functional decline among persons with Alzheimer disease. This trial underscores the burden undertaken by caregivers as they provide care for family members with Alzheimer disease and the difficulty in slowing functional decline. PRIMARY FUNDING SOURCE: National Institute on Aging.
Authors: M F Weiner; E Koss; K V Wild; D G Folks; P Tariot; H Luszczynska; P Whitehouse Journal: Alzheimer Dis Assoc Disord Date: 1996 Impact factor: 2.703
Authors: Christopher M Callahan; Malaz A Boustani; Michael Weiner; Robin A Beck; Lee R Livin; Jeffrey J Kellams; Deanna R Willis; Hugh C Hendrie Journal: Aging Ment Health Date: 2011-01 Impact factor: 3.658
Authors: Christopher M Callahan; Wanzhu Tu; Kathleen T Unroe; Michael A LaMantia; Timothy E Stump; Daniel O Clark Journal: J Am Geriatr Soc Date: 2015-07-22 Impact factor: 5.562
Authors: Laura N Gitlin; Laraine Winter; Janice Burke; Nancy Chernett; Marie P Dennis; Walter W Hauck Journal: Am J Geriatr Psychiatry Date: 2008-03 Impact factor: 4.105
Authors: Laura N Gitlin; Rosa R Baier; Eric Jutkowitz; Zachary G Baker; Allison M Gustavson; Justine S Sefcik; Nancy A Hodgson; Sokha Koeuth; Joseph E Gaugler Journal: J Am Geriatr Soc Date: 2020-07 Impact factor: 5.562
Authors: Gary Arendash; Haitham Abulaban; Susan Steen; Ross Andel; Yanhong Wang; Yun Bai; Rob Baranowski; Jon McGarity; Lyle Scritsmier; Xiaoyang Lin; Ning Shen; Ali Aljassabi; Yitong Li; Chuanhai Cao Journal: Medicines (Basel) Date: 2022-08-03
Authors: Norma B Coe; R Tamara Konetzka; Melissa Berkowitz; Emily Blecker; Courtney H Van Houtven Journal: Annu Rev Public Health Date: 2021-01-04 Impact factor: 21.981
Authors: Sally Bennett; Kate Laver; Sebastian Voigt-Radloff; Lori Letts; Lindy Clemson; Maud Graff; Jodie Wiseman; Laura Gitlin Journal: BMJ Open Date: 2019-11-11 Impact factor: 2.692